MedCity News June 29, 2022
In less than one year, ReCode Therapeutics has reeled in $200 million in financing. Big pharmaceutical companies are taking notice of the biotech startup’s technology, which enables lipid nanoparticles to go a wide range of organs and tissues, potentially broadening the reach of genetic medicines.
ReCode Therapeutics was formed around new science potentially enabling delivery of genetic medicines to various organs in the body, and the startup has encouraging data for its therapeutic candidates targeting the lungs. Now the biotech startup has $120 million to show that it can deliver on the technology’s promise in other organs and cell types in the body.
The financing announced Wednesday was co-led by Leaps by Bayer and AyurMaya, an affiliate of Matrix Capital...
Today's Sponsors
Today's Sponsor